Kuros Biosciences (Formally known as Cytos Biotech; Merged with Kuros Biosurgery)
37 articles about Kuros Biosciences (Formally known as Cytos Biotech; Merged with Kuros Biosurgery)
XOMA Acquires Royalty and Milestone Interest in Checkmate’s Vidutolimod (CMP-001) from Kuros Biosciences
XOMA Corporation, announced it has acquired the royalty interest position Kuros Biosciences holds in Checkmate Pharmaceuticals’ vidutolimod, an advanced-generation Toll-like receptor 9 agonist packaged in a virus-like particle, for $7.0 million upfront plus sales milestones.
Clinical Catch-Up: September 2-8
9/9/2019Last week was a busy week for clinical trial results. Here’s a look at some of the top stories and reporting.
Kuros Biosciences Signs Agreement with Surgical Specialties on Distribution of MagnetOs in Australia and New Zealand
Kuros Biosciences announced that its Dutch subsidiary, Kuros Biosciences BV, has signed a distribution agreement for the Australian and New Zealand healthcare markets with Surgical Specialties, a subsidiary of the Paragon Care Group, a leading provider of medical equipment, devices and consumables.
Biotech Movers and Shakers Aug. 27
8/27/2018Who made a splash in the biotech world this week? Here are some notable people.
Kuros Biosciences Appoints Chief Medical Officer
Kuros Biosurgery Holding Ltd. Closes Merger With Cytos Biotechnology Ltd. Which Is Renamed Kuros Biosciences
LSP’s Portfolio Company Kuros Biosciences Closes Merger With Cytos And Is Now Listed As Kuros Biosciences Ltd On Swiss Stock Exchange
Cytos Biotechnology Ltd. Will Be Renamed Kuros Biosciences , Constitutes Its Board Of Directors And Appoints Executive Officers
VC-Backed Kuros Biosurgery Merges with Cytos Biotech
Cytos Biotechnology AG's Asthma Drug CYT003 Flunks Pivotal Phase 2b Study
Cytos Biotechnology AG Rights Offering Oversubscribed - CHF 24.3 Million Raised
Cytos Biotechnology AG to Host Investor and Analyst R&D Day in New York City
Cytos Biotechnology AG Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma
Cytos Biotechnology AG Reports Second Quarter 2013 Financial Results and Recent Developments
A*STAR and Cytos Biotechnology AG Bring Singapore's First Influenza Vaccine to Clinical Testing
Cytos Biotechnology AG Reports First Quarter 2013 Financial Results and Recent Development
The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study Results With Cytos Biotechnology AG’s CYT003 for the Treatment of Allergic Asthma
Cytos Biotechnology AG VLP Platform is Basis for Phase 1 Clinical Trial with Anti-IgE Vaccine
Cytos Biotechnology AG Reports Third Quarter 2012 Financial Results, Recent Development and Outlook
Cytos Biotechnology AG Appoints Dr. Christian Itin as Chief Executive Officer